Ceapro Closes a Loan Agreement with Symrise AG

Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or "the Company") is very pleased to
announce the signing of a Loan Agreement with its major partner, Symrise, a
German-based multinational company.


"This significant financial support from Symrise fully provides Ceapro with the
required capital to complete the construction and implementation of the state of
the art facility in Edmonton," said Gilles Gagnon, President and CEO of Ceapro.
"This loan from Symrise follows the signing earlier this year of a long-term
Distribution Agreement between Symrise and Ceapro. We are again delighted and
honoured with this recognition and vote of confidence from such a highly
respected international player in our industry," he added.


"This Agreement is further evidence of the long-term partnership between Ceapro
and Symrise and we look forward to the next steps in joining forces and
competencies for the development of new products and new markets," said Dr.
Klaus Stanzl, President and CEO, Life Essentials Division, Symrise Ag.


About Ceapro Inc.

Ceapro Inc. is a Canadian growth-stage biotechnology company. Primary business
activities relate to the development and commercialization of active ingredients
for personal care and cosmetic industries using proprietary technology and
natural, renewable resources. To learn more about Ceapro, visit www.ceapro.com. 


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Branko Jankovic
Vice President and CFO
Ceapro Inc.
Telephone (Edmonton): 780.917.8376
Email: [e-mail]